Drug Database
IN

influenza vaccine (Pandyflu)

✓ Approved

Panacea Biotec Limited · Vaccine · Vaccine

What is influenza vaccine?

influenza vaccine is a vaccine developed by Panacea Biotec Limited. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesPandyflu
CompanyPanacea Biotec Limited
Drug ClassVaccine, Large Molecules
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Panacea Biotec Limited

Related Research Articles

PubMedImmune network2026-09-04

Qualitative Superiority, Not Magnitude, of Lung-Resident CD8+ T Cells Determines Protective Efficacy of Influenza NP Versus PB1 Vaccines.

Lee Serin S, Jang Eunju E, Chang Jun J

T cell-based universal influenza vaccines aim to generate robust lung-resident memory CD8+ T cells (TRM), yet it remains unclear whether conserved Ags elicit equally protective TRM pools. We compared recombinant adenoviral vectors expressing the influenza A nucleoprotein (rAd/NP) or polymerase basic protein 1 (PB1). After intranasal immunization, both induced comparable magnitudes of respiratory Ag-specific CD8+ T cells, yet only rAd/NP provided 100% survival after lethal influenza challenge. This disparity reflected qualitative differences in the TRM pool; nucleoprotein (NP)-specific cells were predominantly CD103-CD49a+, a phenotype associated with superior cytotoxicity, whereas PB1-specific cells were mainly CD103+CD49a-. Furthermore, NP-specific CD8+ T cells showed 100-fold higher functional avidity and stronger lung-local CTL activity than PB1-specific cells. Our findings demonstrate that TRM quality-specifically phenotypic bias and functional avidity-rather than magnitude, are the primary determinants of vaccine-mediated protection. This study underscores the critical importance of Ag selection in optimizing T cell-based universal vaccine strategies.

PMID 42694057
Read full article →
PubMedNature reviews. Rheumatology2026-09-04

Vaccination considerations in autoimmune rheumatic diseases.

Kapetanovic Meliha C MC

Patients with autoimmune rheumatic diseases (ARDs) are at increased risk of numerous vaccine-preventable infections owing to a combination of disease-related immune dysregulation, immunosuppressive therapies - including glucocorticoids - and comorbidities. Age-related immunosenescence further increases this susceptibility in older patients. The SARS-CoV-2 (COVID-19) pandemic and measles outbreaks have underscored the importance of optimizing vaccination strategies and improving adherence to recommendations. Nevertheless, coverage for routinely recommended vaccines, including influenza and pneumococcal vaccines, remains suboptimal in this population. Vaccine hesitancy is an important barrier driven by concerns regarding safety, tolerability, disease flares and the potential induction of new autoimmune phenomena. Advanced therapies - including B cell-depleting agents, chimeric antigen receptor T cell therapy and bispecific T cell engagers - can substantially impair vaccine-induced immune responses, highlighting the importance of optimizing vaccination timing in relation to treatment. Although most studies focus on humoral and cellular immune responses, evidence on the long-term durability of vaccine-induced immunity, the need for booster doses and real-world vaccine effectiveness in patients with ARDs remains limited. Ethical considerations are important. Although vaccination in adults is generally not mandatory, improving vaccine uptake reduces the burden of infections in patients with ARDs, contributes to herd immunity and provides indirect protection for other vulnerable populations.

PMID 42693283
Read full article →
PubMedImmune network2026-09-04

Conserved Influenza Epitopes Delivered via MHC-I-Functionalized Nanocarriers Induce Influenza-Specific CTL Responses.

Kim Sang-Hyun SH, Padasas Bill Thaddeus BT, Kim Dong-Su DS, Kim Doo-Jin DJ et al.

Seasonal influenza evades vaccine-induced immunity via ongoing antigenic drift, highlighting the critical necessity for universal vaccines that elicit broadly cross-reactive CD8+ T cell responses targeting conserved internal viral epitopes. In pursuit of this objective, we prepared biocompatible and biodegradable poly(lactic-co-glycolic acid) (PLGA) nanocarriers (NCs) and functionalized them with MHC-I molecules. Among various murine and human epitopes tested, PB1703-711 and M158-66 showed the highest stabilization of H-2Kb and HLA-A2.1 molecules, respectively, thereby promoting sustained Ag presentation. These NCs exhibited specific peptide-loading onto MHC-I molecules while minimizing non-specific peptide surface binding. In vivo immunization of C57BL/6 mice with PB1703-711-loaded NCs elicited epitope-specific CD8+ T cell responses. Furthermore, the successful specific peptide-loading of HLA-A2.1-attached NCs highlighted the system's human translational applicability. Ultimately, by combining effective Ag delivery with specific CTL induction, this designed NC platform provides a promising strategy for developing next-generation universal vaccines.

PMID 42694026
Read full article →
PubMedInfluenza and other respiratory viruses2026-09-04

Influenza Vaccination Effectiveness in Preventing Hospitalization of Adults With Underlying Medical Conditions: A Multicentre Case-Control Study.

Toledo Diana D, Soldevila Núria N, Galan Juan Carlos JC, Godoy Pere P et al.

Seasonal influenza, especially in persons with underlying medical conditions, is a substantial global burden. Influenza vaccination effectiveness (VE) varies annually, requiring continuous evaluation due to evolving viruses and vaccination coverages. Our aim was to investigate influenza VE in preventing hospitalization for confirmed influenza among people aged 15-64 years with underlying medical conditions. We conducted a multicentre case-control study across 17 Spanish hospitals in hospitalized patients aged 15-64 years with underlying medical conditions in three influenza seasons. Influenza VE was estimated using two types of controls: test-negative controls and non-acute respiratory infection controls. Data on demographics, underlying medical conditions, vaccination status and clinical outcomes were collected. Adjusted VE was analysed using multivariable logistic regression models. Recruited were 1220 hospitalized adults with underlying medical conditions, of whom 25.2% were vaccinated. VE varied by season, age group, and virus subtype. Statistically significant protection was observed for all seasons jointly against influenza A(H3N2) subtype, whereas VE estimates for specific seasons and subtypes were not significant. These findings underscore the importance of continuous VE monitoring and tailored vaccination strategies to protect adults with underlying medical conditions and highlight low seasonal influenza vaccination coverage in this population. Influenza seasonal vaccination should be improved in people aged 15-64 years with underlying medical conditions.

PMID 42693773
Read full article →
PubMedThe Milbank quarterly2026-09-04

Vaccine Policy: The State Role in a Time of Public Health Disruption.

Rosenbaum Sara S

Policy Points Over the past year, the nation's highest-ranking public health officials have pursued a concerted strategy of degrading access to childhood vaccines and undermining public confidence in vaccine safety and efficacy. As primary regulators of medical care, states have the power to maintain strong public health protections. A strong childhood vaccination policy has three components: maintaining a robust routine childhood vaccination schedule; focusing on broad vaccine access; and restoring public confidence in the safety and efficacy of childhood immunization. Beginning in 2025, longstanding opponents of vaccines have held the highest positions of federal public health policy powers. Using these powers, high ranking officials have sought to disrupt vaccine coverage and delivery and sow public mistrust in vaccine safety and efficacy. The results of their efforts have been confusion and declining levels of childhood immunization. As of summer 2026, a federal court has enjoined efforts to degrade the childhood vaccine schedule and the public health expertise of the Advisory Committee on Immunization Practices, whose recommendations lie at the heart of US vaccine policy. As the nation's most important regulators of public health practice, states play a critical role in countering these efforts and protecting vaccine accessibility and acceptance.

PMID 42693907
Read full article →
PubMedFrontiers in pediatrics2026-09-04

Clinical and epidemiological profiles of six respiratory pathogens in hospitalized children in Lixin County, Anhui, China (2024-2025).

Xu Tong T, Wu Xiaolei X, Lin Fang F

Acute respiratory infections are caused by a diverse range of pathogens. This study aimed to investigate the epidemiological profiles and clinical features of major respiratory pathogens by analyzing their detection rates in hospitalized pediatric patients. Nasopharyngeal swab specimens were retrospectively enrolled from pediatric inpatients diagnosed with acute respiratory infections at the Department of Pediatrics, Lixin County People's Hospital, between February 2024 and August 2025. All specimens were subjected to polymerase chain reaction (PCR) assays targeting six major respiratory pathogens, namely adenovirus, respiratory syncytial virus, influenza A virus, influenza B virus, parainfluenza virus, and Mycoplasma pneumoniae. Based on the PCR results, we further delineated the epidemiological trends, age-stratified distribution, and corresponding clinical profiles associated with each identified pathogen. The epidemiological and clinical profiles of the six detected respiratory pathogens are summarized below. In brief, the overall positivity rate of pathogens exhibited winter-spring predominance, with adenovirus and RSV showing the broadest outbreak windows (November-July and November-May, respectively), while influenza A was more restricted (December-March). Mycoplasma pneumoniae displayed a sporadic annual pattern without a statistically significant seasonal peak. Age distribution varied substantially: RSV targeted children < 3 years, M. pneumoniae affected those > 1 year, and influenza A showed a slight infant-toddler predominance. Clinically, while fever and cough were universal, RSV was distinguished by a significantly elevated wheezing rate (27.57% vs. 3.97%-9.52% for others), Febrile seizures were most frequently observed in influenza A virus infections (6.29%), followed by adenovirus (3.57%). Dyspnea or cyanosis was uniformly rare across all pathogens (≤ 0.45%). During the winter season, multiple respiratory pathogens tend to circulate actively. Acute respiratory infections caused by different pathogens exhibit distinct age distributions and clinical manifestations. These features, when combined with local epidemiological data, may assist clinicians in promptly identifying the likely causative pathogen.

PMID 42694336
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about influenza vaccine